Differences in the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis
Authors:
- 21 March 2014
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (10) , 900-909
Abstract
Aims: To compare the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 ( GLP ‐1) analogues between Asians and non‐Asians with type 2 diabetes. Methods: We searched randomized controlled trials from MEDLINE , EMBASE , LILACS , CENTRAL and ClinicalTrials.gov . Studies described in English were included if the treatment duration was 12 weeks or more, information about ethnicity and baseline HbA1c values were available and a GLP ‐1 analogue was compared with a placebo. For the ethnic comparison, we divided the studies into Asian‐dominant studies (≥50% Asian participants) and non‐Asian‐dominant studies (<50% Asian participants). Results: Among the 837 searched studies, 15 trials were included for the meta‐analysis. The weighted mean difference of HbA1c with GLP ‐1 analogues was −1.16% [95% confidence interval ( CI ) −1.48, −0.85] in the Asian‐dominant studies and −0.83% (95% CI −0.97, −0.70) in the non‐Asian‐dominant studies. The between‐group difference was −0.32% (95% CI −0.64, −0.01; p = 0.04). The relative risk ( RR ) with 95% CIs for achieving the target HbA1c ≤7.0% tended to be greater in the Asian‐dominant studies [ RR 5.7 (3.8, 8.7)] than in the non‐Asian‐dominant studies [ RR 2.8 (2.4, 3.3)]. Body weight changes were similar between the two groups. Hypoglycaemia tended to be more common in Asian‐dominant studies ( RR 2.8 [2.3, 3.5]) than in non‐Asian‐dominant studies ( RR 1.5 [1.2, 1.8]), but severe hypoglycaemia was very rare in both groups. Conclusion: GLP ‐1 analogues lower HbA1c more in Asian‐dominant studies than in non‐Asian‐dominant studies. Further studies are warranted to explore the potential mechanisms of the ethnic difference.Keywords
This publication has 43 references indexed in Scilit:
- Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)Diabetes Therapy, 2012
- Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)Diabetes, Obesity and Metabolism, 2012
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in MonotherapyDiabetes Care, 2012
- Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of TreatmentDiabetes Care, 2012
- Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trialDiabetic Medicine, 2010
- Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on MetforminDiabetes Care, 2010
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylureaDiabetes Research and Clinical Practice, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008